AxoGen, Inc. reiterated revenue guidance for the year 2023. The company reiterated its full year guidance with 2023 revenue in the range of $154 million to $159 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.15 USD | -3.51% |
|
+2.14% | +4.69% |
05-28 | Axogen, Inc. Announces the Opening of its Axogen Processing Center | CI |
05-16 | AxoGen Initiates Rolling Submission to FDA For Avance Nerve Graft | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.69% | 324M | |
+7.23% | 217B | |
+11.31% | 188B | |
+28.94% | 153B | |
+32.00% | 112B | |
-0.30% | 62.84B | |
+16.09% | 52.35B | |
+0.80% | 49.33B | |
+1.23% | 35.4B | |
+23.40% | 30.9B |
- Stock Market
- Equities
- AXGN Stock
- News AxoGen, Inc.
- Axogen, Inc. Reiterates Revenue Guidance for the Year 2023